Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The resistance of methicillin-resistant Staphylococcus aureus (MRSA) to all β-lactam classes limits treatment options for serious infections involving this organism. Our goal is to discover new agents that restore the activity of β-lactams against MRSA, an approach that has led to the discovery of two classes of natural product antibiotics, a cyclic depsipeptide (krisynomycin) and a lipoglycopeptide (actinocarbasin), which potentiate the activity of imipenem against MRSA strain COL. We report here that these imipenem synergists are inhibitors of the bacterial type I signal peptidase SpsB, a serine protease that is required for the secretion of proteins that are exported through the Sec and Tat systems. A synthetic derivative of actinocarbasin, M131, synergized with imipenem both in vitro and in vivo with potent efficacy. The in vitro activity of M131 extends to clinical isolates of MRSA but not to a methicillin-sensitive strain. Synergy is restricted to β-lactam antibiotics and is not observed with other antibiotic classes. We propose that the SpsB inhibitors synergize with β-lactams by preventing the signal peptidase-mediated secretion of proteins required for β-lactam resistance. Combinations of SpsB inhibitors and β-lactams may expand the utility of these widely prescribed antibiotics to treat MRSA infections, analogous to β-lactamase inhibitors which restored the utility of this antibiotic class for the treatment of resistant Gram-negative infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Diep, B. A., Gill, S. R., Chang, R. F., Phan, T. H., Chen, J. H., Davidson, M. G., Lin, F., Lin, J., Carleton, H. A., Mongodin, E. F., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68231-7 · Cited by 1,633
Paetzel, M., Karla, A., Strynadka, N. C. J., & Dalbey, R. E. (2002) · Chemical Reviews · doi:10.1021/cr010166y · Cited by 440
Cited by
Actinomycetes: Still a source of novel antibiotics
Genilloud, O. (2017) · Natural Product Reports · doi:10.1039/c7np00026j · Cited by 465
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Optimized arylomycins are a new class of Gram-negative antibiotics
Smith, P. A., Koehler, M. F. T., Girgis, H. S., Yan, D., Chen, Y., Chen, Y., Crawford, J. J., Durk, M. R., Higuchi, R. I., Kang, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0483-6 · Cited by 355
Bacterial proteases, untapped antimicrobial drug targets
Culp, E., & Wright, G. D. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.138 · Cited by 244
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Metadata
- Authors
- Therien, A. G., Huber, J. L., Wilson, K. E., Beaulieu, P., Caron, A., Claveau, D., Deschamps, K., Donald, R. G. K., Galgoci, A. M., Gallant, M., Gu, X., Kevin, N. J., Lafleur, J., Leavitt, P. S., Lebeau-Jacob, C., Lee, S. S., Lin, M. M., Michels, A. A., Ogawa, A. M., Painter, R. E., Parish, C. A., Park, Y.-W., Benton-Perdomo, L., Petcu, M., Phillips, J. W., Powles, M. A., Skorey, K. I., Tam, J., Tan, C. M., Young, K., Wong, S., Waddell, S. T., & Miesel, L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-09
- Volume
- 56
- Issue
- 9
- Pages
- 4662-4670
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1995808283
- Cited by
- 76
- References
- 3
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I. https://app.cochat.ai/papers/10.1128/aac.00726-12
- The paper
- Therien, A. G., Huber, J. L., Wilson, K. E., Beaulieu, P., Caron, A., Claveau, D., Deschamps, K., Donald, R. G. K., Galgoci, A. M., Gallant, M., Gu, X., Kevin, N. J., Lafleur, J., Leavitt, P. S., Lebeau-Jacob, C., Lee, S. S., Lin, M. M., Michels, A. A., Ogawa, A. M., . . . Miesel, L. (2012). Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00726-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.